UK Earnings, Trading Statements Calendar | |
Friday, May 1 | |
Colt Group | Q1 Interim Management Statement |
Lloyds Banking Group | Q1 Interim Management Statement |
Capital & Counties | Trading Statement |
Jardine Lloyd Thompson | Interim Management Statement |
Rentokil | Q1 Interim Management Statement |
Monday, May 4 | |
No Events Scheduled | |
Tuesday, May 5 | |
Glencore | Q1 Production Report |
HSBC Holdings | Q1 Interim Management Statement |
Greene King | Trading Statement |
Aberdeen Asset Management | Half Year Results |
Wednesday, May 6 | |
Carillion | Interim Management Statement |
NCC Group | Interim Management Statement |
GlaxoSmithKline | Q1 Results |
CRH | Interim Management Statement |
DS Smith | Trading Statement |
Direct Line Insurance Group | Q1 Interim Management Statement |
Imperial Tobacco Group | Half Year Results |
IAG | April Traffic Statistics |
Legal & General Group | Q1 Interim Management Statement |
J Sainsbury | Full Year Results |
JD Wetherspoon | Q3 Interim Management Statement |
Sage Group | Half Year Results |
Supergroup | Q4 Results |
National Express | Q1 Interim Management Statement |
GKN | Interim Management Statement |
Intu Properties | Trading Statement |
Thursday, May 7 | |
Aviva | Q1 Interim Management Statement |
Wm Morrison Supermarkets | Interim Management Statement |
Telecity | Q1 Interim Management Statement |
Beazley | Q1 Interim Management Statement |
Esure Group | Q1 Interim Management Statement |
Millennium & Copthorne Hotels | Q1 Results |
Provident Financial Group | Interim Management Statement |
EasyJet | April Traffic Statistics |
BT Group | Q4 Results |
RSA Insurance | Q1 Interim Management Statement |
Trinity Mirror | Trading Statement |
Kennedy Wilson Europe Real Estate | Q1 Interim Management Statement |
IMI | Interim Management Statement |
Copyright 2015 Alliance News Limited. All Rights Reserved. |
IN BRIEF: Malin Corp investee signs agreement with Astellas Pharma
Malin Corp PLC - Dublin-based investor in life sciences companies - Investee company Poseida Therapeutics Inc enters into a research collaboration and licensing agreement with Xyphos Biosciences Inc, a wholly owned subsidiary of Astellas Pharma Inc. Says agreement is to develop novel convertibleCAR programs by combining the innovative cell therapy platforms from each of the companies.
Read more